Comparing the current results to its competitors, Incyte reported Revenue increase in the 1 quarter 2026 by 20.87 % year on year. The sales growth was above Incyte's competitors' average revenue growth of 14.1 %, achieved in the same quarter.
Incyte Corporation Net Income in the 1 quarter 2026 grew year on year by 91.73%, while most of its competitors have experienced a contraction in net income by -28 %.
Incyte's Comment on Competition and Industry Peers
The company utilizes patents, trademarks, trade secrets, copyrights, and contractual agreements to protect its intellectual property, which is essential to its business and competitive position. Its portfolio includes patents and patent applications related to its drug products and candidates, and it seeks patent term extensions in multiple countries. However, these patents may not always be valid, enforceable, or adequate to safeguard its technology or maintain a competitive advantage. Competitors may bypass, challenge, or invalidate the company's patents, and other entities may hold patents that could restrict the company's ability to market its drug candidates without obtaining licenses. The company may need to engage in litigation or other proceedings to defend or enforce its intellectual property rights, which could involve significant costs and unfavorable outcomes.
June 13, 2025
Incyte s Advancements in Cancer Treatment: Promising Phase 3 Data for Retifanlimab and Strong Revenue Growth Amidst Competitive ChallengesIn the ever-evolving landscape of oncology, few developments spark as much interest as groundbreaking clinical trial results. Incyte Corporation (Nasdaq: INCY) has recently captured attention with the release of pivotal Phase 3 data for retifanlimab (trade name: Zynyz), its humanized monoclonal antibody targeting programmed death receptor-1 (PD-1). This significant advancement has been published in the esteemed journal, The Lancet , detailing its impact on adult patients suffering from locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) who h...
September 26, 2024
Incyte to Showcase Cutting-Edge Dermatology and Oncology Data at 2024 Medical Conferences Wilmington, Delaware Incyte Corporation (Nasdaq: INCY) is set to present a comprehensive range of new data from its dermatology and oncology portfolios at several high-profile upcoming medical conferences. The presentations will highlight Incyte’s innovative approaches to tackling various serious health conditions. Dermatology Advances at EADV 2024Incyte has announced the presentation of numerous critical data abstracts at the European Academy of Dermatology and Venereology (EADV) Congress, scheduled to take place from September 25 to 28, 2024, in Amsterdam. These presentations will focus on advancements in treatm...
August 16, 2024
Incyte Delivers Promising News: Tafasitamab Shows Efficacy in Phase 3 Study for Relapsed or Refractory LymphomaIn a significant development for the oncology community, Incyte Corporation (NASDAQ: INCY) announced encouraging topline results from its Phase 3 inMIND study evaluating tafasitamab (branded as Monjuvi) in patients with relapsed or refractory follicular lymphoma (FL). This study investigated the efficacy and safety of tafasitamab, a humanized Fc-modified cytolytic monoclonal antibody targeting CD19, in combination with lenalidomide and rituximab versus lenalidomide and rituximab alone.As the burden of lymphoid malignancies continues to challenge medical practitioners, this new data shines a light o...
August 15, 2024
FDA Approves Niktimvo for Treatment of Chronic Graft-Versus-Host Disease WILMINGTON, Del. and WALTHAM, Mass. Incyte (Nasdaq: INCY) and Syndax Pharmaceuticals (Nasdaq: SNDX) announced today that the U.S. Food and Drug Administration (FDA) has approved Niktimvo (axatilimab-csfr) for the treatment of chronic graft-versus-host disease (GVHD). This significant development comes after patients have failed to respond to at least two prior systemic therapies.Niktimvo is a monoclonal antibody targeting CSF-1R, a cell surface protein involved in the regulation of immune responses. The approval from the FDA allows its use in both adult and pediatric patients weighing at least 40 kilograms (approximately 88.2 pounds) ...
May 16, 2024
Incyte, a leading biopharmaceutical company specializing in oncology, has recently announced that it will be presenting data from its oncology portfolio at two major medical conferences in 2024. The American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled to take place from May 31st to June 4th in Chicago, and the European Hematology Association Congress 2024 (EHA2024), which will be held from June 13th to 16th in Madrid, Spain, as well as virtually.These presentations mark an important milestone for Incyte, as it highlights their ongoing commitment to researching and developing innovative therapies to address the unmet needs of cancer patients. With a diverse range of candidates in various sta...
Precigen Inc is a biotechnology company that focuses on the development and commercialization of innovative genetic therapies. Their business model revolves around leveraging their proprietary technologies and expertise in gene editing and synthetic biology to create transformative medical solutions. With a strong emphasis on research and development, Precigen aims to bring cutting-edge genetic therapies to market and address critical unmet medical needs.
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
Merck & Co. Inc. operates primarily as a research-driven pharmaceutical company, focused on the development, manufacturing, and marketing of prescription drugs and vaccines globally. It aims to address unmet medical needs through innovative research, collaborations, and rigorous clinical trials, while promoting patient well-being and contributing to global healthcare with high-quality, affordable medications.
Sources:
Incyte Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Incyte Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
